SCHEDULE: Coastlands Capital Discloses 9.98% Stake in Adial Pharma

Coastlands Capital LP and affiliates have reported a 9.98% beneficial ownership stake in Adial Pharmaceuticals, Inc. as of June 17, 2026.

Summary

• Coastlands Capital LP, along with its affiliates and Matthew D. Perry, filed a Schedule 13G reporting a 9.98% beneficial ownership in Adial Pharmaceuticals, Inc.
• The reporting group holds 262,167 shares of common stock.
• The ownership percentage is based on 2,625,943 total shares outstanding as of June 17, 2026.
• The filing confirms the acquisition was made in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; it is a standard regulatory disclosure of institutional ownership that does not signal a change in company fundamentals or management strategy.

Positives

• Institutional investor interest indicates potential confidence in the company's long-term prospects.
• The filing confirms the investment is passive, suggesting no immediate intent to disrupt corporate strategy.

Negatives

• The reporting group holds pre-funded warrants that are excluded from the 9.98% calculation due to a 4.99% beneficial ownership limitation, implying potential future dilution if these are exercised.

Risks

• The concentration of ownership by an institutional investor may lead to increased share price volatility.
• Potential future dilution exists due to the existence of pre-funded warrants held by the reporting persons.

Future Outlook

The filing does not provide specific forward-looking guidance regarding the company's operations, but confirms the reporting persons' intent to hold the securities in the ordinary course of business.

Industry Context

StockSavvy.ai notes that institutional filings of this nature are common in the small-cap pharmaceutical sector, where specialized investment firms often take significant positions in companies undergoing clinical trials or seeking capital, reflecting a broader trend of institutional support for biotech development.

Comparison to Industry Standards

• The 9.98% stake is a standard threshold for institutional investors to report under Schedule 13G, consistent with typical passive investment strategies in the micro-cap biotech space.
• The use of a 4.99% beneficial ownership limitation on warrants is a standard practice for institutional investors to avoid triggering change-of-control reporting requirements prematurely.

Stakeholder Impact

• Shareholders may view the entry of an institutional investor as a sign of external validation.
• Existing shareholders should be aware of the potential for future dilution from the exercise of pre-funded warrants.

Next Steps

• The reporting persons will continue to monitor their investment in the ordinary course of business.
• Future filings may be required if there are material changes to the percentage of ownership.

Key Dates

Keywords

Adial Pharmaceuticals, ADIL, Schedule 13G, Coastlands Capital, Institutional Ownership, Beneficial Ownership